MedTrace Logo

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-07-11

No results posted yet for this study

Summary

A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders

Conditions

  • Idiopathic Parkinson Disease

Interventions

COMBINATION_PRODUCT

CTC-413

pramipexole ER, given with aprepitant

Sponsors & Collaborators

  • Chase Therapeutics Corporation

    lead INDUSTRY

Principal Investigators

  • Kitty Clarence-Smith, md · KM Pharmaceutical Consulting

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2025-12-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03683225 on ClinicalTrials.gov